Physician profile
Jay Pearcy
NPI 1558304600
$2,992.68
in general payments reported to CMS, 2019-2025
19 companies · $201 in 2025
The $201 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $730 · 2020: $305 · 2021: $533 · 2022: $498 · 2023: $335 · 2024: $391 · 2025: $201.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $927.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $926.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $925.65 | 2019-2024 | |
| Janssen Biotech, INC. | $463.60 | 2019-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $399.58 | 2022-2025 | Sotyktu |
| Lilly USA, LLC | $269.95 | 2019-2024 | Taltz, Ebglyss |
| Novartis Pharmaceuticals Corporation | $212.55 | 2019-2025 | |
| Amgen INC. | $144.26 | 2020-2024 | Otezla |
| Ucb, INC. | $104.60 | 2019-2025 | Bimzelx |
| Celgene Corporation | $81.79 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $65.84 | 2019 | |
| Sun Pharmaceutical Industries INC. | $63.19 | 2022-2023 | Ilumya |
| Pfizer INC. | $59.19 | 2020-2021 | |
| Galderma Laboratories, L.P. | $48.50 | 2021-2025 | Nemluvio |
| Leo Pharma INC. | $38.51 | 2021 | |
| Kyowa Kirin, INC. | $28.09 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $22.82 | 2024 | Libtayo |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $19.57 | 2021 | |
| Dermira, INC. | $17.13 | 2020 | |
| Biofrontera INC. | $16.07 | 2023 | Ameluz, Xepi, Bf-Rhodoled |
| Merck Sharp & Dohme LLC | $11.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Pearcy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.